August 18, 2026 · Science · Biomarkers

What happened

Researchers at the University of Toledo reported a fast whole-blood test that detects elevated bile acids, a marker of liver dysfunction that standard liver panels tend to miss. As described by MedicalXpress, the assay measures how well red blood cell membranes resist osmotic stress, which shifts when bile acids build up in the blood, a condition called cholemia. The team validated it by comparing 23 patients with cholestatic liver disease to 23 age- and gender-matched controls without liver disease, and in genetic mouse models. The work was published in the American Journal of Physiology-Gastrointestinal and Liver Physiology (DOI: 10.1152/ajpgi.00096.2026).

The short version

This is an early research result, not a test you can buy. It is worth a note because bile acids are a liver signal the panels sold by consumer platforms do not measure, and because it shows how far ahead research markers run before they reach a panel you can order. The read for a longevity buyer is a reality check on breadth claims, not a new test to seek out.

What it means for you

Bile acids are not in the standard liver workup. A routine panel reports enzymes and proteins such as ALT, AST, alkaline phosphatase, GGT and bilirubin, and those are also the liver markers that consumer longevity panels include. The researchers argue that bile-acid buildup is an early and overlooked signal, which is why a simple way to measure it could matter clinically. For a reader tracking liver health through a testing platform, the practical takeaway is narrow: the markers you can act on today remain the standard enzymes, and this assay is not among the options.

The stage of the evidence sets the ceiling on how much to make of it. The human validation rests on 46 people total at one medical center, in a cross-sectional comparison rather than a trial that followed people over time. The report says the method consistently separated patients with elevated bile acids from those without, but it gives no sensitivity, specificity, or accuracy numbers, and it has not been reproduced by an independent group. The mouse models strengthen the biological case without adding human proof. A patent application has been filed, which points toward eventual development, not toward a test on a shelf. None of this makes the finding weak for what it is. It makes it early, and early research is a poor basis for a personal testing decision.

There is a benchmark angle worth naming. Platforms in this space compete partly on how many markers a panel covers, and marketing leans on the biggest number available. A research assay for a marker no consumer panel offers is a useful counterweight to that framing. Panel breadth is a snapshot of what happened to be validated and commercialized, not a measure of everything a body could be showing. The frontier of what a blood draw might reveal sits well ahead of what any product can sell you, and a bigger marker count does not close that gap.

How this fits what we already publish

Our biomarker guides cover the liver markers that appear on real panels, including GGT and alkaline phosphatase, and how to read them without over-interpreting a single flagged value. This research does not change any of that guidance. We are noting it because readers ask why one panel measures more markers than another, and the structural answer is that panels track validated, orderable tests, which always trail the research literature. If a bile-acid assay like this one is ever validated at scale and offered commercially, we will cover it then.

Sources

  • MedicalXpress, "Researchers develop blood test targeting overlooked marker of liver disease," medicalxpress.com (accessed August 18, 2026).
  • American Journal of Physiology-Gastrointestinal and Liver Physiology, DOI: 10.1152/ajpgi.00096.2026 (accessed August 18, 2026).

Frequently Asked Questions

Can I get this bile-acid test today?

No. It is a research assay, not a commercial test. The University of Toledo team has filed a patent application (number 18844313), per MedicalXpress, which is a step toward development, not availability. There is no route to order it for yourself right now.

Do standard liver panels already measure bile acids?

Not usually. A routine liver panel measures enzymes and proteins such as ALT, AST, ALP, GGT and bilirubin. Bile acids are not part of that standard set, which is the gap the researchers say their test addresses. Our guides to GGT and alkaline phosphatase cover the liver markers that panels do include today.

How strong is the evidence so far?

Early. The human validation compared 23 patients with cholestatic liver disease to 23 matched controls at a single medical center, a small cross-sectional design, alongside genetic mouse models. The report states the method consistently separated the two groups but gives no sensitivity, specificity, or accuracy figures. Small single-center results need larger, independent validation before they mean anything for routine care.

Should I ask my doctor about bile-acid testing?

Bile-acid measurement is already used in specific clinical situations, such as evaluating cholestasis in pregnancy, through existing lab tests ordered by a clinician. This news is about a new research method, not a new reason to test. Any concern about liver health is a conversation for your own clinician, who can decide what testing is appropriate.